Peptomyc
Phase 2Peptomyc is a spin-off from the Vall d’Hebron Institute of Oncology (VHIO) that is revolutionizing cancer treatment: we are the only company that uses mini-protein therapeutics to directly inhibit MYC – the central engine for cancer proliferation, survival, and resistance to treatment. Doing so, Peptomyc offers a foundational treatment to any cancer patient with abnormal MYC activity, improving patient’ survival and quality of life.
About
Peptomyc is a spin-off from the Vall d’Hebron Institute of Oncology (VHIO) that is revolutionizing cancer treatment: we are the only company that uses mini-protein therapeutics to directly inhibit MYC – the central engine for cancer proliferation, survival, and resistance to treatment. Doing so, Peptomyc offers a foundational treatment to any cancer patient with abnormal MYC activity, improving patient’ survival and quality of life.
Funding History
3Total raised: $40.8M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile